CRISPR Therapeutics AG (CRSP) has a current Price-to-Book (P/B) ratio of 2.63. Compared to its 3-year average P/B ratio of 2.38, the current P/B ratio is approximately 10.48% higher. Relative to its 5-year average P/B ratio of 2.62, the current P/B ratio is about 0.70% higher. CRISPR Therapeutics AG (CRSP) has a Forward Free Cash Flow (FCF) yield of approximately -5.92%. Compared to its 3-year average FCF yield of -5.97%, the current FCF yield is approximately -0.88% lower. Relative to its 5-year average FCF yield of -3.71%, the current FCF yield is about 59.50% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CRSP competitors is 189.83, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP.O) exhibits a P/S ratio of 176.75, which is -6.89% above the industry average. Given its robust revenue growth of -97.58%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CRSP increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CRSP in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CRSP currently overvalued or undervalued?

What is CRISPR Therapeutics AG (CRSP) fair value?

CRSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of CRISPR Therapeutics AG (CRSP) is between 28.48 to 61.78 according to relative valuation method.

How does CRSP's valuation metrics compare to the industry average?

The average P/S ratio for CRSP's competitors is 189.83, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP) exhibits a P/S ratio of 176.75, which is -6.89% above the industry average. Given its robust revenue growth of -97.58%, this premium appears unsustainable.

What is the current P/B ratio for CRISPR Therapeutics AG (CRSP) as of Mar 03 2026?

As of Mar 03 2026, CRISPR Therapeutics AG (CRSP) has a P/B ratio of 2.63. This indicates that the market values CRSP at 2.63 times its book value.

What is the current FCF Yield for CRISPR Therapeutics AG (CRSP) as of Mar 03 2026?

As of Mar 03 2026, CRISPR Therapeutics AG (CRSP) has a FCF Yield of -5.92%. This means that for every dollar of CRISPR Therapeutics AG's market capitalization, the company generates -5.92 cents in free cash flow.

What is the current Forward P/E ratio for CRISPR Therapeutics AG (CRSP) as of Mar 03 2026?

As of Mar 03 2026, CRISPR Therapeutics AG (CRSP) has a Forward P/E ratio of -12.00. This means the market is willing to pay $-12.00 for every dollar of CRISPR Therapeutics AG's expected earnings over the next 12 months.

What is the current Forward P/S ratio for CRISPR Therapeutics AG (CRSP) as of Mar 03 2026?

As of Mar 03 2026, CRISPR Therapeutics AG (CRSP) has a Forward P/S ratio of 176.75. This means the market is valuing CRSP at $176.75 for every dollar of expected revenue over the next 12 months.

CRSP Valuation